Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting

Clinical Therapeutics

Volumn 36, Issue 12, 2014, Pages 2015-2028.e2

  Zheng, Ying ^a   Sorensen, Sonja V ^a   Gonschior, Ann Katrin ^b   Noack, Herbert ^b   Heinrich Nols, Jutta ^b   Sunderland, Tom ^c   Kansal, Anuraag R ^a  

^a EVIDERA   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

anticoagulation; apixaban; atrial fibrillation; cost effectiveness; dabigatran; rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACUTE HEART INFARCTION; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM; ATRIAL FIBRILLATION; BLEEDING; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; ECONOMICS; EMBOLISM; GREAT BRITAIN; STROKE; THEORETICAL MODEL;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; DABIGATRAN; EMBOLISM; GREAT BRITAIN; HEMORRHAGE; HUMANS; MODELS, THEORETICAL; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RIVAROXABAN; STROKE; WARFARIN;

EID: 84916917857     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.09.015     Document Type: Article

References (45)

1. J. Heeringa, D.A. van der Kuip, and A. Hofman Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 2006 949 953
2. D.J. Gladstone, E. Bui, and J. Fang Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated Stroke 40 2009 235 240
3. C. Marini, F. De Santis, and S. Sacco Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study Stroke 36 2005 1115 1119
4. J. Ansell, J. Hirsh, and E. Hylek Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 6 Suppl 2008 160S 198SS
5. A.M. Gallagher, S. Rietbrock, J. Plumb, and T.P. van Staa Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 6 2008 1500 1506
6. National Institute for Health and Care Excellence (NICE). TA249: Dabigatran Etexilate for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation. London, England: National Institute for Health and Care Excellence; 2012.
7. National Institute for Health and Care Excellence (NICE). TA275: Apixaban for Preventing Stroke and Systemic Embolism in People With Nonvalvular Atrial Fibrillation 2012 National Institute for Health and Care Excellence London, England
8. National Institute for Health and Care Excellence (NICE). TA256: Rivaroxaban for the Prevention of Stroke and Systemic Embolism in People With Atrial Fibrillation 2012 National Institute for Health and Care Excellence London, England
9. S. Ghanny, and M. Crowther Treatment with novel oral anticoagulants: indications, efficacy and risks Curr Opin Hematol 20 2013 430 436
10. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
11. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
12. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
13. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
14. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. NICE article PMG9 (Process and methods guides) April, 2013; http://www.nice.org.uk/article/pmg9/chapter/foreword. Accessed February 28, 2014.
15. S.V. Sorensen, A.R. Kansal, and S. Connolly Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective Thromb Haemost 105 2011 908 919
16. A.R. Kansal, S.V. Sorensen, and R. Gani Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation Heart 98 2012 573 578
17. G.Y. Lip, R. Nieuwlaat, and R. Pisters Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
18. J Rosand, MH Eckman, and KA Knudsen The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage Arch Intern Med 164 2004 880 884
19. SH Hohnloser, J Oldgren, and S Yang Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial Circulation 125 2012 669 676
20. HC Bucher, GH Guyatt, LE Griffith, and SD. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
21. M Jones, P McEwan, and CL Morgan Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 91 2005 472 477
22. FDA. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC): Rivaroxaban (XARELTO®) Tablets. NDA 202439. September 8, 2011; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf. Accessed January 26, 2012.
23. AR Kansal, M Sharma, and C Bradley-Kennedy Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: comparative efficacy and cost-effectiveness Thromb Haemost 108 2012 672 682
24. RD Lopes, SM Al-Khatib, and L Wallentin Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial Lancet 380 2012 1749 1758
25. NS Roskell, GY Lip, and H Noack Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate Thromb Haemost 104 2010 1106 1115
26. SJ Edwards, V Hamilton, and N Trevor Apixaban for the Prevention of Stroke and Systemic Embolism in People With Non-valvular Atrial Fibrillation: STA Report 2012 BMJ Technology Assessment Group London, England
27. KF Huybrechts, JJ Caro, JJ Xenakis, and KN. Vemmos The prognostic value of the modified Rankin Scale score for long-term survival after first-ever stroke: results from the Athens Stroke Registry Cerebrovasc Dis 26 2008 381 387
28. Group. Haymarket Media MIMS Online: Prescription Drug Database and Drug Prescribing Guide 2013 Haymarket Media Group London, England
29. R Luengo-Fernandez, GS Yiin, AM Gray, and PM. Rothwell Population-based study of acute- and long-term care costs after stroke in patients with AF Int J Stroke 8 2013 308 314
30. Personal Social Services Research Unit. Cost of one GP visit inflated to 2013. In: Unit Costs of Health and Social Care 2012 2012 Personal Social Services Research Unit London, England
31. Personal Social Services Research Unit. Unit Costs of Health and Social Care 2012 2012 Personal Social Services Research Unit London, England
32. PW Sullivan, TW Arant, SL Ellis, and H. Ulrich The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US Pharmacoeconomics 24 2006 1021 1033
33. BF Gage, AB Cardinalli, and DK. Owens The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life Arch Intern Med 156 1996 1829 1836
34. PW Sullivan, JF Slejko, MJ Sculpher, and V. Ghushchyan Catalogue of EQ-5D scores for the United Kingdom Med Decis Making 31 2011 800 804
35. AH Briggs, BJ O'Brien, and G. Blackhouse Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies Annu Rev Public Health 23 2002 377 401
36. GY Lip, JL Halperin, and HF. Tse The 2010 European Society of Cardiology Guidelines on the management of atrial fibrillation: an evolution or revolution? Chest 139 2011 738 741
37. L Testa, M Agnifili, and RA Latini Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation QJM 105 2012 949 957
38. S Mantha, and J. Ansell An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation Thromb Haemost 108 2012 476 484
39. Wells G, Coyle D, Cameron C, et al. Therapeutic Review: Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation. April 9, 2012. http://www.cadth.ca/media/pdf/NOAC-Therapeutic-Review-final-report.pdf. Accessed February 28, 2014
40. O'Day K, Globe D. Using Net Benefits to Report Cost-Effectiveness Results. Paper presented at ISPOR 14th Annual European Congress (International Society for Pharmacoeconomics and Outcomes Research), in Madrid, Spain, 6-9 November. 2011; http://www.ispor.org/congresses/Spain1111/presentations/W30-Globe-Oday.pdf. Accessed February 28, 2014.
41. D Coyle, K Coyle, and C Cameron Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation Value Health 16 2013 498 506
42. AR Harrington, EP Armstrong, PE Nolan Jr, and DC. Malone Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Stroke 44 2013 1676 1681
43. J Pink, M Pirmohamed, and DA. Hughes Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation Clin Pharmacol Ther 94 2013 269 276
44. GY Lip, T Kongnakorn, and H Phatak Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation Clin Ther 36 192-210 2014 192 210 e20
45. Mahaffey KW, Fox KAA, on behalf of Rocket-AF Investigators. ROCKET-AF: Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation. 2012; https://www.dcri.org/research/slides-presentations/ROCKET-AF-LBCT-FINAL.ppt/at-download/file. Accessed February 28, 2014